store at low temperature | store at -20°C
Patritumab(U3-1287)是抗 HER3 单克隆抗体,具有潜在的抗肿瘤活性,对 EGFR,HER2,HER3,ERK 和 AKT 的磷酸化有抑制作用和。Patritumab 促使细胞凋亡 (apoptosis),抑制非小细胞肺癌的增殖。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,320 | 现货 | ||
2 mg | ¥ 3,480 | 现货 | ||
5 mg | ¥ 5,630 | 现货 | ||
10 mg | ¥ 7,880 | 现货 | ||
25 mg | ¥ 11,700 | 现货 | ||
50 mg | ¥ 15,700 | 现货 | ||
100 mg | ¥ 21,200 | 现货 |
产品描述 | Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer. |
体外活性 | Patritumab targets the extracellular domain (ECD) of HER3 and induces apoptosis in DiFi-HRG4 cells (10 μg/mL; 5 days)[1]. Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT in DiFi-HRG4 cells without affecting that of ERK[1]. Additionally, Patritumab (10 μg/mL; 48 h) induces the cleavage of PARP, accompanied by both up-regulation of BIM and down-regulation of survivin expression[1]. |
体内活性 | In a DiFi-HRG tumor xenografts model in mice, Patritumab (1 mg/mouse; intraperitoneal; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity[1]. Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1]. |
别名 | U3-1287, AMG-888 |
分子量 | N/A |
CAS No. | 1262787-83-6 |
store at low temperature | store at -20°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Patritumab 1262787-83-6 Angiogenesis Cytoskeletal Signaling JAK/STAT signaling MAPK PI3K/Akt/mTOR signaling Tyrosine Kinase/Adaptors EGFR ERK Akt HER U3-1287 AMG-888 Inhibitor inhibitor inhibit